Please login to the form below

Not currently logged in
Email:
Password:

bone cancer

This page shows the latest bone cancer news and features for those working in and with pharma, biotech and healthcare.

Bluebird and Celgene BCMA CAR-T kicks off ASCO

Bluebird and Celgene BCMA CAR-T kicks off ASCO

Bluebird and Celgene BCMA CAR-T kicks off ASCO. Will be reporting updated phase I trial data for bb2121in patients with bone marrow cancer. ... option for patients with metastatic squamous non-small cell lung cancer (NSCLC) - regardless of PD-L1

Latest news

  • Unsure on efficacy, NICE passes J&J’s Darzalex to CDF Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

    Unsure on efficacy, NICE passes J&J’ s Darzalex to CDF. The bone marrow cancer therapy is now temporarily approved as a fourth-line treatment. ... who have failed other drugs for the blood cancer, promoting J&J to ask for a review of fourth-line use.

  • Roche gets FDA OKs for Alecensa and Zelboraf Roche gets FDA OKs for Alecensa and Zelboraf

    Roche gets FDA OKs for Alecensa and Zelboraf. Gains US licences for first-line use in lung cancer and a rare blood cancer. ... ECD is a slow-growing cancer that originates in the bone marrow and leads to excessive production of white blood cells know as

  • FDA fast-tracks Astellas' Rydapt rival FDA fast-tracks Astellas' Rydapt rival

    The FDA gave the status to gilteritinib as a treatment for adults with FLT3-mutation-positive relapsed or refractory acute myeloid leukaemia (AML), a cancer that impacts blood and bone marrow. ... According to the American Cancer Society, 21, 000

  • NICE finally set to back wider use of Ferring's Firmagon NICE finally set to back wider use of Ferring's Firmagon

    It follows a protracted appeals process over 2014 guidance that had limited use of the prostate cancer drug to a narrow patient population. ... can provide immediate reduction of cancer in the bone and stop this awful condition taking hold.

  • Imbruvica wins wider European leukaemia licence Imbruvica wins wider European leukaemia licence

    Despite Imbruvica's status as the most requested CLL drug available on the Cancer Drugs Fund (CDF), the cost-effectiveness watchdog claimed that it was not minded to approve an NHS ... A slow-progressing cancer of the bone marrow and blood cancer, CLL is

More from news
Approximately 2 fully matching, plus 72 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis. ... Janssen granted Tracon Pharmaceuticals the rights to

  • Case study: Treatment guidance Case study: Treatment guidance

    Challenge. Mifamurtide is a treatment for children, adolescents and young adults with a rare type of bone cancer, osteosarcoma.

  • Case study: Treatment guidance Case study: Treatment guidance

    Challenge. Mifamurtide is a treatment for children, adolescents and young adults with a rare type of bone cancer, osteosarcoma.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Jakavi (rare bone marrow disorder); Signifor (Cushing's disease) plus 16 products in 24 pivotal trials. ... Additional revenues for these two drugs are also promised in other cancer types not to mention their “ combo” potential.

  • The distressing impact of rare diseases The distressing impact of rare diseases

    A US patient with Multiple Hereditary Exostosis (that can cause bone cancer) quoted in the report said: “ Finding a doctor that can treat me is the most difficult part.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics